¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2021³âµµ ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ Á¦24Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2021-07-02

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2021³âµµ ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ Á¦24Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2021-07-02
±³À°ÀÏÀÚ : 2021-07-02
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021³âµµ ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ Á¦24Â÷ Çмú´ëȸ (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ
´ã´çÀÚ : ÀÌÇѳª
¿¬¶ôó : 02-401-1570  
À̸ÞÀÏ : kscm.office@gmail.com      
±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú¹Ì»ý¹°ÇÐ
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 14 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 250,000¿ø      
ºñ°í Á¤È¸¿ø 10¸¸¿ø, ÁØȸ¿ø 5¸¸¿ø, ´Üüȸ¿ø 10¸¸¿ø, ºñȸ¿ø 25¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 07:30~08:30 ME1: Troubleshooting of SARS-CoV2 Real Time RT-PCR  ¼ºÈï¼·(¿ï»êÀÇ´ë) 
È޽Ġ07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 08:30~09:00 Break/exhibition  () 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 09:00~10:00 Oral Presentation I  () 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 10:00~11:00 Oral Presentation II  () 
È޽Ġ07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 11:00~11:10 Break/exhibition  () 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 11:10~12:00 Surveillance by Objectives (SBO): an old but precious concept for fighting antimicrobial resistance (AMR) in Korea  Mark Miller(McGill University) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 12:00~12:30 Updates in diagnosis of drug-resistant tuberculosis  ±èâ±â(¼­¿ïÀÇ°úÇבּ¸¼Ò) 
È޽Ġ07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 13:00~13:30 Clinical application of NGS for SARS-CoV-2 or X  À̱âÇö(õ·¦¹ÙÀÌ¿À) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 13:30~14:00 Building laboratory capacity for Pandemic X  ÀÌÇõ¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 14:00~14:30 Emerging infectious diseases other than SARS-CoV2  ÀÌÁ¾À±(ºÎ»êÀÇ´ë) 
È޽Ġ07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 14:30~14:50 Break/exhibition  () 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 14:50~15:20 Periodic preemptive screening method of SARS-CoV-2 for healthcare workers  À̾ç¼ø(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 15:20~15:50 Application of rapid diagnostics on preemptive screening of carbapenemase-producing Enterobacteriales  Á¤Çý¼±(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö µ¥ÀÌÁö·ë 15:50~16:20 Preoperative search and destroy for Staphylococcus aureus surgical site infections  ÀåÁ¤Çö(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 07:30~08:30 ME2: Troubleshooting of Antimicrobial Susceptibility Testing  ¹ÚÁ¤¼ö(¼­¿ïÀÇ´ë) 
È޽Ġ07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 08:30~09:00 Break/exhibition  () 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 09:00~09:30 Past & future of the GLASS  Á¤Åë·É(WHO) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 09:30~10:00 AMR national action plan & KOR-GLASS  ÃÖÁرæ(Áúº´°ü¸®Ã») 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 10:00~10:30 Burden of major AMR pathogens causing bloodstream infections  ±èµµ±Õ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 10:30~11:00 Current AMR status of Acinetobacter baumannii & emerging colistin resistance  ±è¿µ¾Æ(±¹¹Î°Ç°­º¸Çè°ø´Ü Àϻ꺴¿ø) 
È޽Ġ07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 11:00~11:10 Break/exhibition  () 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 11:10~12:00 Surveillance by Objectives (SBO): an old but precious concept for fighting antimicrobial resistance (AMR) in Korea  Mark Miller(McGill University) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 12:00~12:30 COVID-19: What We Thought We Knew, What We Think We Know, and What We Don¡¯t Know  Norman Moore(Abbott) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 13:00~13:30 Accelerated diagnostics for infectious diseases based on culture or non-culture  ¹Ú¿¬ÁØ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 13:30~14:00 Rapid detection of antimicrobial resistance  ÃÖ±ÔÅÂ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 14:00~14:30 Clinical implication of metagenomics  ¿ëµ¿Àº(¿¬¼¼ÀÇ´ë) 
È޽Ġ07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 14:30~14:50 Break/exhibition  () 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 14:50~15:20 Application of MALDI-TOF in clinical microbiology  ¿À¿¹Áø(³ì½ÊÀÚ) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 15:20~15:50 How handy is an Isothermal amplification kit?  ¹è¹ÌÇö(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 07-02 ¿¤Å¸¿ö Áö´Ï¾Æ·ë 15:50~16:20 Good or bad lateral flow immunoassay  Á¤Àç¿ì(µ¿±¹ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2021³âµµ ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ Á¦24Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2021-07-02""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ¿Ü»óÇÐȸ (¿Â¶óÀÎ) The 8th Pan-Pacific Trauma Congress 2021 Korea : 2021-07-02
´ÙÀ½±Û (¿Â¶óÀÎ) ±¹¸³¾Ï¼¾ÅÍ ¾Ï°úÇÐÆ÷·³ ½Å¾à°³¹ß A-Z(Small moleculeÀÇ °³¹ß/Ãʱ⹰Áú ¹ß±¼ Áß½É) : 2021-07-02
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 50 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 44 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 44 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 52 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 38 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 76 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 29 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 43 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 39 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 47 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 47 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 33 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 37 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 44 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 46 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷